These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Extent of surgery for differentiated thyroid cancer. Dackiw AP; Zeiger M Surg Clin North Am; 2004 Jun; 84(3):817-32. PubMed ID: 15145237 [TBL] [Abstract][Full Text] [Related]
4. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma. Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882 [TBL] [Abstract][Full Text] [Related]
5. [The importance of recombinant human thyroid stimulating hormone in the follow-up and treatment of disseminated thyroid cancer after thyroidectomy]. Skoura E; Rontogianni P Hell J Nucl Med; 2007; 10(1):40-7. PubMed ID: 17450254 [TBL] [Abstract][Full Text] [Related]
6. Medical management of persistent or recurrent differentiated thyroid carcinoma. Jun JY; Manni A Otolaryngol Clin North Am; 2008 Dec; 41(6):1241-60, xi-xii. PubMed ID: 19040983 [TBL] [Abstract][Full Text] [Related]
7. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation. Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522 [TBL] [Abstract][Full Text] [Related]
8. Management of follicular and Hürthle cell neoplasms of the thyroid gland. McHenry CR; Sandoval BA Surg Oncol Clin N Am; 1998 Oct; 7(4):893-910. PubMed ID: 9735140 [TBL] [Abstract][Full Text] [Related]
9. Contemporary management of papillary carcinoma of the thyroid gland. Rosenbaum MA; McHenry CR Expert Rev Anticancer Ther; 2009 Mar; 9(3):317-29. PubMed ID: 19275510 [TBL] [Abstract][Full Text] [Related]
10. [Basic policy for postsurgical follow-up of patients with differentiated thyroid carcinoma--guidelines from abroad]. Hamada N Nihon Rinsho; 2007 Nov; 65(11):2061-7. PubMed ID: 18018571 [TBL] [Abstract][Full Text] [Related]
11. Hürthle cell carcinoma: a clinicopathological study of thirteen cases. Ozlem Küçük N; Kulak H; Tokmak E; Tar P; Ibiş E; Aras G Nucl Med Commun; 2006 Apr; 27(4):377-9. PubMed ID: 16531925 [TBL] [Abstract][Full Text] [Related]
12. [Taking of position in relationship to the protocol of the current treatment of thyroid nodules and differentiated thyroid cancer]. Gómez Sáez JM Endocrinol Nutr; 2010 Oct; 57(8):370-5. PubMed ID: 20850397 [No Abstract] [Full Text] [Related]
13. The evolving role of (131)I for the treatment of differentiated thyroid carcinoma. Robbins RJ; Schlumberger MJ J Nucl Med; 2005 Jan; 46 Suppl 1():28S-37S. PubMed ID: 15653649 [TBL] [Abstract][Full Text] [Related]
15. Thyroglobulin: a specific serum marker for the management of thyroid carcinoma. Whitley RJ; Ain KB Clin Lab Med; 2004 Mar; 24(1):29-47. PubMed ID: 15157556 [TBL] [Abstract][Full Text] [Related]
16. Papillary thyroid cancer: monitoring and therapy. Tuttle RM; Leboeuf R; Martorella AJ Endocrinol Metab Clin North Am; 2007 Sep; 36(3):753-78, vii. PubMed ID: 17673127 [TBL] [Abstract][Full Text] [Related]
17. [Follow-up care for differentiated thyroid cancer]. Hüfner M; Reiners C Dtsch Med Wochenschr; 1986 Nov; 111(45):1732-4. PubMed ID: 3536387 [No Abstract] [Full Text] [Related]
18. Current issues in the management of differentiated thyroid cancer. Mallick UK; Charalambous H Nucl Med Commun; 2004 Sep; 25(9):873-81. PubMed ID: 15319591 [No Abstract] [Full Text] [Related]
19. [Diagnosis, treatment and follow-up in the case of differentiated thyroid cancer]. Lind P; Igerc I; Kohlfürst S Wien Med Wochenschr; 2005 Oct; 155(19-20):429-35. PubMed ID: 16424998 [TBL] [Abstract][Full Text] [Related]
20. Thyroid cancer: an overview. Haq M; Harmer C Nucl Med Commun; 2004 Sep; 25(9):861-7. PubMed ID: 15319589 [No Abstract] [Full Text] [Related] [Next] [New Search]